Mizuho Boosts UiPath (NYSE:PATH) Price Target to $25.00

UiPath (NYSE:PATH) had its target price upped by Mizuho from $22.00 to $25.00 in a research report released on Thursday morning, Benzinga reports. Mizuho currently has a neutral rating on the healthcare company’s stock.

Several other equities analysts also recently commented on PATH. TD Cowen increased their price objective on shares of UiPath from $25.00 to $28.00 and gave the company an outperform rating in a research note on Thursday. Needham & Company LLC raised their price objective on UiPath from $25.00 to $30.00 and gave the stock a buy rating in a research report on Thursday. Morgan Stanley increased their price target on UiPath from $17.00 to $25.00 and gave the stock an equal weight rating in a report on Thursday. Barclays increased their target price on shares of UiPath from $23.00 to $25.00 and gave the stock an equal weight rating in a research note on Friday. Finally, BMO Capital Markets upped their price objective on shares of UiPath from $24.00 to $28.00 and gave the company a market perform rating in a report on Thursday. Nine equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, UiPath has a consensus rating of Hold and a consensus price target of $27.13.

UiPath Trading Up 1.4 %

UiPath stock traded up $0.32 during trading hours on Thursday, reaching $23.07. 9,842,354 shares of the stock were exchanged, compared to its average volume of 10,074,664. UiPath has a twelve month low of $12.38 and a twelve month high of $27.87. The company has a market cap of $13.06 billion, a P/E ratio of -135.46 and a beta of 0.97. The stock has a 50 day moving average of $23.52 and a two-hundred day moving average of $20.70.

Insiders Place Their Bets

In other UiPath news, CFO Ashim Gupta sold 16,000 shares of the company’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $22.47, for a total transaction of $359,520.00. Following the completion of the sale, the chief financial officer now directly owns 103,505 shares in the company, valued at $2,325,757.35. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other news, CFO Ashim Gupta sold 16,000 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $22.47, for a total value of $359,520.00. Following the transaction, the chief financial officer now owns 103,505 shares in the company, valued at $2,325,757.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Rich Wong sold 200,000 shares of the company’s stock in a transaction on Monday, January 8th. The shares were sold at an average price of $23.12, for a total transaction of $4,624,000.00. Following the sale, the director now owns 429,418 shares of the company’s stock, valued at $9,928,144.16. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 411,000 shares of company stock valued at $9,418,670. 31.03% of the stock is currently owned by corporate insiders.

Institutional Trading of UiPath

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PATH. Mark Sheptoff Financial Planning LLC purchased a new stake in shares of UiPath in the 4th quarter worth about $25,000. HighMark Wealth Management LLC purchased a new stake in UiPath in the fourth quarter worth about $27,000. Tyler Stone Wealth Management bought a new position in shares of UiPath in the 2nd quarter worth approximately $28,000. Cypress Capital Management LLC WY purchased a new position in shares of UiPath in the 4th quarter valued at approximately $29,000. Finally, Fifth Third Bancorp raised its holdings in UiPath by 2,005.3% in the third quarter. Fifth Third Bancorp now owns 2,000 shares of the healthcare company’s stock worth $34,000 after purchasing an additional 1,905 shares in the last quarter. Hedge funds and other institutional investors own 59.04% of the company’s stock.

About UiPath

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.